- Terazosin
-
- $999.00 / 1KG
-
2022-02-25
- CAS:63590-64-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1 ton
- Terazosin
-
- $19.99 / 1KG
-
2022-02-25
- CAS:63590-64-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20KG
- Terazosin
-
- $15.60 / 1KG
-
2022-02-25
- CAS:63590-64-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1000tons
|
| | Terazosin Basic information |
| Product Name: | Terazosin | | Synonyms: | 1-(4-aMino-6,7-diMethoxy-quinazolin-2-yl)-4-(tetrahydrofuran-2-carbonyl)-piperazine;TERAZOSIN(HYTRIN);Prazosin Tetrahydro IMpurity;Hytrin：Hytrinex;Urodie;Vasomet：Vicard;1-(4-Amino-6，7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbowl]piperazine;Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-
| | CAS: | 63590-64-7 | | MF: | C19H25N5O4 | | MW: | 387.43 | | EINECS: | 613-265-8 | | Product Categories: | API's;API;Terazosin;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 63590-64-7.mol |  |
| | Terazosin Chemical Properties |
| Melting point | 281-283°C | | Boiling point | 664.5±65.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | H2O: 25 mg/mL | | pka | pKa (0.1N NaOH): 7.1(at 25℃) | | form | powder | | color | white to off-white | | Water Solubility | 30.6mg/L(22.5 ºC) | | BCS Class | 1/3 | | InChIKey | VCKUSRYTPJJLNI-UHFFFAOYSA-N | | CAS DataBase Reference | 63590-64-7(CAS DataBase Reference) |
| | Terazosin Usage And Synthesis |
| Chemical Properties | White to Off-White Crystalline Powder | | Uses | Terazosin is used for the same indications as is prazosin; however, it has the advantage of
being able to be used once a day. | | Uses | An α-1-adrenergicblocker related to prazosin. | | Uses | An a-1-adrenergicblocker related to prazosin | | Definition | ChEBI: Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. | | Clinical Use | Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH) | | Synthesis | Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-
piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a
tetrahydrofuryl radical. It is synthesized in exactly the same manner except using
1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51]. | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination. | | Metabolism | Terazosin is metabolised in the liver; one of the
metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the
urine, as unchanged drug and metabolites. |
| | Terazosin Preparation Products And Raw materials |
|